Literature DB >> 32160890

Risk stratification for early bacteremia after living donor liver transplantation: a retrospective observational cohort study.

Jaesik Park1, Bae Wook Kim1, Ho Joong Choi2, Sang Hyun Hong1, Chul Soo Park1, Jong Ho Choi1, Min Suk Chae3.   

Abstract

BACKGROUND: This study investigated perioperative clinical risk factors for early post-transplant bacteremia in patients undergoing living donor liver transplantation (LDLT). Additionally, postoperative outcomes were compared between patients with and without early post-transplant bacteremia.
METHODS: Clinical data of 610 adult patients who underwent elective LDLT between January 2009 and December 2018 at Seoul St. Mary's Hospital were retrospectively collected. The exclusion criteria included overt signs of infection within 1 month before surgery. A total of 596 adult patients were enrolled in this study. Based on the occurrence of a systemic bacterial infection after surgery, patients were classified into non-infected and infected groups.
RESULTS: The incidence of bacteremia at 1 month after LDLT was 9.7% (57 patients) and Enterococcus faecium (31.6%) was the most commonly cultured bacterium in the blood samples. Univariate analysis showed that preoperative psoas muscle index (PMI), model for end-stage disease score, utility of continuous renal replacement therapy (CRRT), ascites, C-reactive protein to albumin ratio, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio, and sodium level, as well as intraoperative post-reperfusion syndrome, mean central venous pressure, requirement for packed red blood cells and fresh frozen plasma, hourly fluid infusion and urine output, and short-term postoperative early allograft dysfunction (EAD) were associated with the risk of early post-transplant bacteremia. Multivariate analysis revealed that PMI, the CRRT requirement, the NLR, and EAD were independently associated with the risk of early post-transplant bacteremia (area under the curve: 0.707; 95% confidence interval: 0.667-0.745; p < 0.001). The overall survival rate was better in the non-infected patient group. Among patients with bacteremia, anti-bacterial treatment was unable to resolve infection in 34 patients, resulting in an increased risk of patient mortality. Among the factors included in the model, EAD was significantly correlated with non-resolving infection.
CONCLUSIONS: We propose a prognostic model to identify patients at high risk for a bloodstream bacterial infection; furthermore, our findings support the notion that skeletal muscle depletion, CRRT requirement, systemic inflammatory response, and delayed liver graft function are associated with a pathogenic vulnerability in cirrhotic patients who undergo LDLT.

Entities:  

Keywords:  Bacteremia; Inflammation; Primary graft dysfunction; Psoas muscles; Renal replacement therapy

Year:  2020        PMID: 32160890     DOI: 10.1186/s12893-019-0658-6

Source DB:  PubMed          Journal:  BMC Surg        ISSN: 1471-2482            Impact factor:   2.102


  3 in total

1.  Stress burden related to postreperfusion syndrome may aggravate hyperglycemia with insulin resistance during living donor liver transplantation: A propensity score-matching analysis.

Authors:  Sumin Chae; Junghee Choi; Sujin Lim; Ho Joong Choi; Jaesik Park; Sang Hyun Hong; Chul Soo Park; Jong Ho Choi; Min Suk Chae
Journal:  PLoS One       Date:  2020-12-10       Impact factor: 3.240

2.  In-hospital mortality of liver transplantation and risk factors: a single-center experience.

Authors:  Xing-Mao Zhang; Hua Fan; Qiao Wu; Xin-Xue Zhang; Ren Lang; Qiang He
Journal:  Ann Transl Med       Date:  2021-03

3.  Clinical application of intraoperative somatic tissue oxygen saturation for detecting postoperative early kidney dysfunction patients undergoing living donor liver transplantation: A propensity score matching analysis.

Authors:  Jaesik Park; Sangmin Jung; Sanghoon Na; Ho Joong Choi; Jung-Woo Shim; Hyung Mook Lee; Sang Hyun Hong; Min Suk Chae
Journal:  PLoS One       Date:  2022-01-21       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.